Literature DB >> 19875634

Overload: impact of incident stressful events on antiretroviral medication adherence and virologic failure in a longitudinal, multisite human immunodeficiency virus cohort study.

Michael J Mugavero1, James L Raper, Susan Reif, Kathryn Whetten, Jane Leserman, Nathan M Thielman, Brian Wells Pence.   

Abstract

OBJECTIVE: To examine the influence of incident stressful experiences on antiretroviral medication adherence and treatment outcomes. Past trauma history predicts poorer medication adherence and health outcomes. Human immunodeficiency virus (HIV)-infected individuals experience frequently traumatic and stressful events, such as sexual and physical assault, housing instability, and major financial, employment, and legal difficulties.
METHODS: We measured prospectively incident stressful and traumatic events, medication adherence, and viral load over 27 months in an eight-site, five-state study. Using multivariable logistic and generalized estimating equation modeling, we assessed the impact of incident stressful events on 27-month changes in self-reported medication adherence and virologic failure (viral load = >or=400 c/mL).
RESULTS: Of 474 participants on antiretroviral therapy at baseline, 289 persons were interviewed and still received treatment at 27 months. Participants experiencing the median number of incident stressful events (n = 9) had over twice the predicted odds (odds ratio = 2.32) of antiretroviral medication nonadherence at follow-up compared with those with no events. Stressful events also predicted increased odds of virologic failure during follow-up (odds ratio = 1.09 per event).
CONCLUSIONS: Incident stressful events are exceedingly common in the lives of HIV-infected individuals and negatively affect antiretroviral medication adherence and treatment outcomes. Interventions to address stress and trauma are needed to improve HIV outcomes.

Entities:  

Mesh:

Year:  2009        PMID: 19875634      PMCID: PMC3691857          DOI: 10.1097/PSY.0b013e3181bfe8d2

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  42 in total

1.  HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.

Authors:  Jonathan Shuter; Julie A Sarlo; Tina J Kanmaz; Richard A Rode; Barry S Zingman
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

2.  You want to measure coping but your protocol's too long: consider the brief COPE.

Authors:  C S Carver
Journal:  Int J Behav Med       Date:  1997

3.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).

Authors:  M A Chesney; J R Ickovics; D B Chambers; A L Gifford; J Neidig; B Zwickl; A W Wu
Journal:  AIDS Care       Date:  2000-06

4.  Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse.

Authors:  Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Ramani S Durvasula; Mona N Lam; Marta Stefaniak
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

Review 5.  HIV disease progression: depression, stress, and possible mechanisms.

Authors:  Jane Leserman
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

6.  Predictors of AIDS-related morbidity and mortality in a southern U.S. Cohort.

Authors:  Michael J Mugavero; Brian Wells Pence; Kathryn Whetten; Jane Leserman; Marvin Swartz; Dalene Stangl; Nathan M Thielman
Journal:  AIDS Patient Care STDS       Date:  2007-09       Impact factor: 5.078

7.  Relation of lifetime trauma and depressive symptoms to mortality in HIV.

Authors:  Jane Leserman; Brian Wells Pence; Kathryn Whetten; Michael J Mugavero; Nathan M Thielman; Marvin S Swartz; Dalene Stangl
Journal:  Am J Psychiatry       Date:  2007-11       Impact factor: 18.112

8.  Childhood sexual abuse and sexual transmission risk behaviour among HIV-positive men who have sex with men.

Authors:  A O'Leary; D Purcell; R H Remien; C Gomez
Journal:  AIDS Care       Date:  2003-02

9.  The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART.

Authors:  Viviane D Lima; Josie Geller; David R Bangsberg; Thomas L Patterson; Mark Daniel; Thomas Kerr; Julio S G Montaner; Robert S Hogg
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

10.  Coping strategies and patterns of alcohol and drug use among HIV-infected patients in the United States Southeast.

Authors:  Brian Wells Pence; Nathan M Thielman; Kathryn Whetten; Jan Ostermann; Virender Kumar; Michael J Mugavero
Journal:  AIDS Patient Care STDS       Date:  2008-11       Impact factor: 5.078

View more
  59 in total

1.  Psychosocial Correlates of Medication Adherence among HIV-Positive, Cognitively Impaired Individuals.

Authors:  Timothy J Arentsen; Stella Panos; April D Thames; J Natalie Arbid; Steven A Castellon; Charles H Hinkin
Journal:  J HIV AIDS Soc Serv       Date:  2016-09-23

2.  Adverse childhood experiences, mental health, substance use, and HIV-related outcomes among persons with HIV.

Authors:  Kelly C Young-Wolff; Varada Sarovar; Stacy A Sterling; Amy Leibowitz; Brigid McCaw; Charles B Hare; Michael J Silverberg; Derek D Satre
Journal:  AIDS Care       Date:  2019-03-19

Review 3.  Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011.

Authors:  Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

4.  Incident stressful and traumatic life events and human immunodeficiency virus sexual transmission risk behaviors in a longitudinal, multisite cohort study.

Authors:  Brian Wells Pence; James L Raper; Susan Reif; Nathan M Thielman; Jane Leserman; Michael J Mugavero
Journal:  Psychosom Med       Date:  2010-07-01       Impact factor: 4.312

Review 5.  Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review.

Authors:  Jessica L Castilho; Vlada V Melekhin; Timothy R Sterling
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

6.  Medication adherence challenges among HIV positive substance abusers: the role of food and housing insecurity.

Authors:  Hilary L Surratt; Catherine L O'Grady; Maria A Levi-Minzi; Steven P Kurtz
Journal:  AIDS Care       Date:  2014-10-14

7.  Impact of stressful death or divorce in people with HIV: A prospective examination and the buffering effects of religious coping and social support.

Authors:  Gail Ironson; Sarah M Henry; Brian D Gonzalez
Journal:  J Health Psychol       Date:  2017-08-25

8.  Tailoring Cognitive Behavioral Therapy for Trauma-Exposed Persons Living With HIV.

Authors:  Cristina M López; Christine K Hahn; Amanda K Gilmore; Carla Kmett Danielson
Journal:  Cogn Behav Pract       Date:  2019-03-14

9.  The impact of stressful life events, symptom status, and adherence concerns on quality of life in people living with HIV.

Authors:  Inge B Corless; Joachim Voss; A J Guarino; Dean Wantland; William Holzemer; Mary Jane Hamilton; Elizabeth Sefcik; Suzanne Willard; Kenn Kirksey; Carmen Portillo; Marta Rivero Mendez; Maria E Rosa; Patrice K Nicholas; Sarie Human; Mary Maryland; Shahnaz Moezzi; Linda Robinson; Yvette Cuca
Journal:  J Assoc Nurses AIDS Care       Date:  2013-03-07       Impact factor: 1.354

10.  Recent partner violence and sexual and drug-related STI/HIV risk among adolescent and young adult women attending family planning clinics.

Authors:  Michele R Decker; Elizabeth Miller; Heather L McCauley; Daniel J Tancredi; Heather Anderson; Rebecca R Levenson; Jay G Silverman
Journal:  Sex Transm Infect       Date:  2013-11-14       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.